Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials

BACKGROUND: A recent meta‐analysis of sodium–glucose cotransporter 2 (SGLT2) inhibitor outcome trials reported that SGLT2 inhibitors were associated with reduction in the risk of adverse composite kidney outcomes, with moderate heterogeneity across the trials; however, the endpoints were defined dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherney, David Z. I., Dagogo‐Jack, Samuel, McGuire, Darren K., Cosentino, Francesco, Pratley, Richard, Shih, Weichung J., Frederich, Robert, Maldonado, Mario, Liu, Jie, Wang, Shuai, Cannon, Christopher P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364727/
https://www.ncbi.nlm.nih.gov/pubmed/34129237
http://dx.doi.org/10.1002/clc.23665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364727/
https://www.ncbi.nlm.nih.gov/pubmed/34129237
http://dx.doi.org/10.1002/clc.23665

Ejemplares similares